Fig. 3: miR-937-5p accounts for MIR937 loss of function in ovarian cancer cells. | Cell Death & Disease

Fig. 3: miR-937-5p accounts for MIR937 loss of function in ovarian cancer cells.

From: MIR937 amplification potentiates ovarian cancer progression by attenuating FBXO16 inhibition on ULK1-mediated autophagy

Fig. 3

Growth curves for OVCAR3 (a) and A2780 (b) cells were monitored by CCK8 analysis upon miR-937-5p or 3p mimics transfection. c, d Growth curves for OVCAR3 and A2780 cells were detected after transfection of miR-937-5p or 3p inhibitors. Growth curves for OVCAR3 (e) and A2780 (f) comparison of MIR937+/+ cells with MIR937−/− cells, into which miR-937-5p or 3p mimics were transfected. MIR937+/+ cells mock transfected, while MIR937−/− cells were transfected with miR-937-5p or 3p mimics (g) The graphical summary for agomiR injection into the xenograft tumors. Xenograft tumors derived from OVCAR3 (h) and A2780 (i) cells were displayed. MIR937+/+ tumors were mock treated with agomiR-NC, and for MIR937−/− tumors, agomiR-937-5p and -937-3p were used to interfere with tumor growth. Growth curve for the xenograft tumors affected by agomiR-937-5p and -937-3p for OVCAR3 (j) and A2780 cells (k). Tumor weights for OVCAR3 (l) and A2780 (m) cells were measured at day 25 when the mice were sacrificed after five rounds of agomiR injection. Data are shown as the mean ± SD. Similar results were obtained in three independent experiments. Statistical analysis was performed using one-way ANOVA in (a–f, j–m); **P < 0.01; ***P < 0.001; ****P < 0.0001.

Back to article page